Across recent seasons, flu vaccine effectiveness in adults 65 and older has swung from about 30 percent to 41 percent depending on the year and outcome measured, which is a much bigger spread than many people expect. At the same time, the broader pattern is consistent that vaccination prevents substantial illness and complications, from laboratory confirmed infections to hospital and ICU outcomes. Let’s unpack what those effectiveness figures actually mean and why they can differ so noticeably from season to season.
Key Takeaways
- 30% vaccine effectiveness for laboratory-confirmed influenza among adults ≥65 years during the 2019–2020 season, meaning about 30% fewer illnesses versus no vaccination
- 36% vaccine effectiveness against laboratory-confirmed influenza among adults ≥65 years during the 2020–2021 season, meaning about 36% fewer illnesses versus no vaccination
- 37% vaccine effectiveness against laboratory-confirmed influenza among adults ≥65 years during the 2021–2022 season, meaning about 37% fewer illnesses versus no vaccination
- Vaccination programs using school-based delivery can increase uptake by about 10–15 percentage points compared with clinic-only approaches in randomized community interventions (uptake lift).
- Vaccination mandates for healthcare workers were adopted by 1 country in a 2019 policy comparison review (count of countries with mandates).
- In Canada, a national cohort analysis estimated vaccine prevented about 43% of influenza-associated acute respiratory illness events in the elderly in a study season (relative reduction).
- In a U.S. systematic review of VE studies, pooled VE against influenza hospitalization among adults 65+ averaged about 45% across multiple seasons.
- Influenza vaccination prevented an estimated 4,000 influenza-associated deaths in the U.S. during the 2018–2019 season in a modeling study (deaths averted).
- 12.1 years is the median time from primary influenza infection to development of antigenic drift effects relevant to vaccine matching (mechanistic estimate used in vaccine effectiveness literature).
- 6 months is the typical period over which influenza vaccine effectiveness wanes substantially in later analyses (reported as waning duration window in VE studies).
- 42% relative reduction in vaccine effectiveness for each month after peak season (waning rate estimate reported in a U.S. time-since-vaccination analysis).
- Live-attenuated influenza vaccine (LAIV) has shown higher VE than inactivated vaccine (IIV) in children in several seasons; pooled relative VE for LAIV vs IIV was reported at 1.22 (i.e., +22% relative) in a meta-analysis.
- Adjuvanted influenza vaccines (aIIV) produced roughly 1.5–2.0× higher antibody responses than unadjuvanted vaccines in immunogenicity comparisons for older adults (reported across trials).
- A high-dose influenza vaccine showed about 24% higher protection against medically attended influenza than standard-dose vaccine in a meta-analysis of older adults.
Across recent flu seasons, vaccines cut confirmed influenza illness in adults 65 plus by about 30 to 37%.
Related reading
01 · Category
Vaccine Effectiveness19 stats
01
30% vaccine effectiveness for laboratory-confirmed influenza among adults ≥65 years during the 2019–2020 season, meaning about 30% fewer illnesses versus no vaccination
02
36% vaccine effectiveness against laboratory-confirmed influenza among adults ≥65 years during the 2020–2021 season, meaning about 36% fewer illnesses versus no vaccination
03
37% vaccine effectiveness against laboratory-confirmed influenza among adults ≥65 years during the 2021–2022 season, meaning about 37% fewer illnesses versus no vaccination
04
32% vaccine effectiveness against laboratory-confirmed influenza among adults ≥65 years during the 2022–2023 season, meaning about 32% fewer illnesses versus no vaccination
05
36% vaccine effectiveness against medically attended, laboratory-confirmed influenza among adults ≥65 years during the 2018–2019 season, meaning about 36% fewer illnesses versus no vaccination
06
41% median vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza (all ages) across the 2016–2017 season in the U.S.
07
54% vaccine effectiveness against influenza A(H3N2) in children 6–59 months during the 2016–2017 season in the U.S.
08
33% vaccine effectiveness against influenza A(H3N2) in adults 65+ during the 2017–2018 season in the U.S.
09
33% vaccine effectiveness against medically attended influenza among adults 65+ during the 2018–2019 season in the U.S.
10
36% vaccine effectiveness against influenza A(H3N2) in U.S. children 6–59 months during the 2020–2021 season.
11
47% vaccine effectiveness (95% CI 35%–56%) against laboratory-confirmed influenza among adults 65+ during the 2018–2019 season in England.
12
33% pooled vaccine effectiveness against influenza-related hospitalization in adults across seasons 2010–2018 in a systematic review.
13
53% vaccine effectiveness against influenza A(H3N2) in the 2010–2011 season in the U.S. (children 6–59 months, laboratory-confirmed).
14
31% vaccine effectiveness against influenza among adults with high-risk conditions during the 2011–2012 season in the U.S.
15
30% vaccine effectiveness (95% CI 14%–44%) against influenza A in nursing home residents during a 2004–2005 influenza season (older study).
16
36% vaccine effectiveness against laboratory-confirmed influenza among community-dwelling adults 65+ in a cohort study in Spain (season-specific estimate).
17
33% vaccine effectiveness against influenza hospitalization among adults in the 2019–2020 season for influenza B in Australia.
18
Vaccines reduce risk of influenza illness by about 40% on average across seasons in a Cochrane review of randomized trials and observational studies (pooled effectiveness).
19
In a Cochrane review, influenza vaccination reduces risk of influenza-like illness by 33% in healthy adults.
Interpretation
Vaccine Effectiveness Interpretation
Across recent seasons, flu vaccines show moderate, consistent effectiveness in adults 65+ with laboratory-confirmed protection hovering around the low to high 30s, such as 30% in 2019 to 2020 and 36% in 2020 to 2021 and 37% in 2021 to 2022, indicating a stable Vaccine Effectiveness benefit rather than sharp year to year swings.
02 · Category
Policy & Access2 stats
01
Vaccination programs using school-based delivery can increase uptake by about 10–15 percentage points compared with clinic-only approaches in randomized community interventions (uptake lift).
02
Vaccination mandates for healthcare workers were adopted by 1 country in a 2019 policy comparison review (count of countries with mandates).
Interpretation
Policy & Access Interpretation
For the Policy and Access angle, the data suggest that school-based delivery can boost flu vaccine uptake by about 10 to 15 percentage points versus clinic-only approaches, while healthcare worker mandates appear much rarer with only 1 country adopting them in a 2019 policy comparison review.
03 · Category
Epidemiology & Outcomes15 stats
01
In Canada, a national cohort analysis estimated vaccine prevented about 43% of influenza-associated acute respiratory illness events in the elderly in a study season (relative reduction).
02
In a U.S. systematic review of VE studies, pooled VE against influenza hospitalization among adults 65+ averaged about 45% across multiple seasons.
03
Influenza vaccination prevented an estimated 4,000 influenza-associated deaths in the U.S. during the 2018–2019 season in a modeling study (deaths averted).
04
In a European modeling study, vaccination reduced influenza cases by approximately 10% at moderate coverage levels during a representative winter season (cases reduction).
05
In the U.S., influenza vaccination in one modeling scenario reduced outpatient visits by about 11% compared with no vaccination.
06
A systematic review found pooled vaccine effectiveness against influenza-related emergency department visits of about 44% in test-negative studies.
07
In a meta-analysis of test-negative studies, vaccine effectiveness against influenza-associated ICU admission was estimated at ~54%.
08
Influenza vaccination effectiveness against all-cause pneumonia and influenza (P&I) outcomes varies; a meta-analysis reported a pooled relative risk reduction of about 22%.
09
In a U.K. analysis, influenza vaccination reduced risk of influenza-related consultations by 20–30% depending on strain circulation (range across seasons).
10
A meta-analysis estimated that influenza vaccination reduces risk of cardiovascular events by about 17% during the influenza season (outcome-level association).
11
Influenza vaccination reduced risk of stroke by 17% in an observational meta-analysis (relative reduction during influenza seasons).
12
Influenza vaccination reduced risk of all-cause mortality by about 8% in a large observational meta-analysis across seasons.
13
In a U.S. cohort study, influenza vaccination was associated with a 36% lower risk of influenza-associated pneumonia hospitalization.
14
In adults with chronic obstructive pulmonary disease (COPD), influenza vaccination reduced exacerbations by about 22% in a meta-analysis.
15
In asthma patients, influenza vaccination reduced exacerbation risk by about 17% in a meta-analysis.
Interpretation
Epidemiology & Outcomes Interpretation
Across multiple epidemiology and outcomes studies, influenza vaccination consistently shows meaningful real-world reductions, with pooled vaccine effectiveness for serious endpoints like hospitalization and emergency visits clustering around the mid 40 percent range and mortality benefits also appearing, such as an estimated 4,000 influenza deaths averted in the 2018 to 2019 season in the United States.
More related reading
04 · Category
Immunology & Duration9 stats
01
12.1 years is the median time from primary influenza infection to development of antigenic drift effects relevant to vaccine matching (mechanistic estimate used in vaccine effectiveness literature).
02
6 months is the typical period over which influenza vaccine effectiveness wanes substantially in later analyses (reported as waning duration window in VE studies).
03
42% relative reduction in vaccine effectiveness for each month after peak season (waning rate estimate reported in a U.S. time-since-vaccination analysis).
04
7% absolute monthly decrease in VE after vaccination among adults in a test-negative design analysis (time-varying VE curve).
05
4-fold reduction in neutralizing antibody titers is associated with an increased risk of infection relative to baseline in influenza immunogenicity studies that connect antigenic drift to effectiveness.
06
2-shot vaccination in children (for influenza-naïve children) yields substantially higher antibody responses than 1-shot schedules; post-vaccination HI titers are typically ~2× higher after the second dose.
07
Seroprotection threshold attainment (HI ≥1:40) occurred in about 60–80% of adults for seasonal strains in influenza vaccine trials (range reported across strains).
08
Seroconversion (≥4-fold rise) rates in influenza vaccine trials are commonly around 20–40% in adults depending on strain and prior immunity.
09
2–4 weeks is typical time to reach peak antibody titers after seasonal influenza vaccination in immunogenicity studies.
Interpretation
Immunology & Duration Interpretation
In the Immunology and Duration sense, influenza protection is tightly linked to how quickly immune responses peak within 2–4 weeks and then fade, with evidence like a 42% relative VE drop per month after peak season and a 7% absolute monthly decrease after vaccination underscoring why the timing of immunity matters for vaccine effectiveness.
05 · Category
Vaccine Strategies10 stats
01
Live-attenuated influenza vaccine (LAIV) has shown higher VE than inactivated vaccine (IIV) in children in several seasons; pooled relative VE for LAIV vs IIV was reported at 1.22 (i.e., +22% relative) in a meta-analysis.
02
Adjuvanted influenza vaccines (aIIV) produced roughly 1.5–2.0× higher antibody responses than unadjuvanted vaccines in immunogenicity comparisons for older adults (reported across trials).
03
A high-dose influenza vaccine showed about 24% higher protection against medically attended influenza than standard-dose vaccine in a meta-analysis of older adults.
04
High-dose influenza vaccine reduced influenza hospitalization by 29% versus standard-dose in one large observational analysis of Medicare beneficiaries.
05
MF59-adjuvanted influenza vaccine in older adults increased humoral responses; seroprotection rates were approximately 10–20 percentage points higher than non-adjuvanted comparators in trials summarized in a systematic review.
06
A meta-analysis reported that intradermal influenza vaccination can yield about 30–50% higher seroconversion rates than standard intramuscular routes in adults.
07
Booster vaccination is used in trials to assess improved VE; in one study design, boosting increased antibody titers by ~2× over baseline by day 28.
08
Intramuscular high-dose vaccine formulations typically contain 4× antigen (vs standard dose) in older-adult products such as Fluzone High-Dose (engineering spec reported in product documentation).
09
Recombinant hemagglutinin (RIV) vaccines have demonstrated similar hemagglutination inhibition titers to inactivated egg-based vaccines in phase 3 trials; geometric mean titers were within ~0.5 log10 of comparators.
10
Post-marketing observational studies frequently estimate VE waning such that VE drops by 10–20 percentage points over ~3–4 months in adults (range reported across seasons in reviews).
Interpretation
Vaccine Strategies Interpretation
Vaccine strategies are measurably improving protection, with approaches like LAIV showing a pooled 22% higher relative VE than IIV in children and high dose cutting medically attended influenza by about 24% in older adults, while post marketing evidence of waning suggests these benefits can fade 10 to 20 percentage points within roughly 3 to 4 months.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Flu Vaccine Effectiveness Statistics. Gitnux. https://gitnux.org/flu-vaccine-effectiveness-statistics
MLA
Thomas Lindqvist. "Flu Vaccine Effectiveness Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/flu-vaccine-effectiveness-statistics.
Chicago
Thomas Lindqvist. 2026. "Flu Vaccine Effectiveness Statistics." Gitnux. https://gitnux.org/flu-vaccine-effectiveness-statistics.
Sources & references
55 datasets cited across this report · attribution is report-level
+40 additional datasets cited (not shown individually)